133909-97-4

Basic information

• Product Name: 4-Methyl-[2'-(2-Trityl-2H-Tetr
• Synonyms: 4-Methyl-[2'-(2-Trityl-2H-Tetr;5-(4'-methyl-[1,1'-biphenyl]-2-yl)-2-trityl-2H-tetrazole;5-[2-(4-METHYLPHENYL)PHENYL]-2-TRIPHENYLMETHYL-TETRAZOLE(WXG00946)
• CAS NO: 133909-97-4
• Molecular Formula: C₃₃H₂₆N₄
• Molecular Weight: 478.596
• Mol File: 133909-97-4.mol
• Article Data: 12

Chemical Properties

• Melting Point: 166-169 °C(Solv: ethyl acetate (141-78-6); dichloromethane (75-09-2))
• Boiling Point: 681.6±65.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• PKA: -0.08±0.12(Predicted)
• CAS DataBase Reference: 4-Methyl-[2'-(2-Trityl-2H-Tetr(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-[2'-(2-Trityl-2H-Tetr(133909-97-4)
• EPA Substance Registry System: 4-Methyl-[2'-(2-Trityl-2H-Tetr(133909-97-4)

Safety Data

• Hazardous Substances Data: 133909-97-4(Hazardous Substances Data)

Usage

Chemical Properties

Off-White to Pale Beige Solid

Uses

Different sources of media describe the Uses of 133909-97-4 differently. You can refer to the following data:
1. 5-(4'-methyl-[1,1'-biphenyl]-2-yl)-2-trityl-2H-tetrazole is an intermediate in the preparation of Candesartan. It is also used in the synthesis of novel biphenyltetrazole derivatives.
2. An intermediate in the preparation of Candesartan. Also used in the synthesis of novel biphenyltetrazole derivatives.

Upstream product

• 76-83-5 trityl chloride 
• 120568-11-8 2-(tetrazol-5-yl)-4'-methyl-1,1'-biphenyl 
• 4294-57-9 para-methylphenylmagnesium bromide 
• 76-84-6 triphenylmethyl alcohol 
• 120568-11-8 5-<4'-Methyl-1,1'-biphenyl-2-yl>-1H-tetrazole 
• 214360-47-1 2-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-benzonitrile 
• 100-47-0 benzonitrile 
• 1336-21-6 ammonium hydroxide 
• 624-31-7 4-tolyl iodide 
• 676-58-4 methylmagnesium chloride 
• 87268-78-8 2-trityl-5-phenyl-2H-tetrazole 
• 145337-52-6 5-(2-iodophenyl)-2-triphenylmethyl-2H-tetrazole 
• 106-38-7 para-bromotoluene 
• 21615-34-9 2-Methoxybenzoyl chloride 

Downstream Products

• 155092-07-2 1-<<2'-<(N-triphenylmethyl)tetrazol-5-yl>biphenyl-4-yl>methyl>-4-butylimidazole-2-carboxaldehyde 
• 1400934-09-9 C₄₁H₃₆N₆O₂ 
• 1400933-86-9 5-butyl-1-[[(2'-(2-trityl)-tetrazol-5-yl)biphenyl-4-yl]methyl]-3-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazolium bromide 
• 1400933-88-1 5-butyl-2-hydroxymethyl-1-[[(2'-(2-trityl)-2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazolium bromide 
• 155091-95-5 5-butyl-2-hydroxymethyl-1-<<2'-<(N-triphenylmethyl)tetrazol-5-yl>biphenyl-4-yl>methyl>imidazole 
• 155091-74-0 5-butyl-2-hydroxymethyl-1-[[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole 
• 1400933-91-6 5-butyl-4-chloro-2-hydroxymethyl-1-[[(2'-(2-trityl)-2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole 
• 1400933-93-8 4-bromo-5-butyl-2-hydroxymethyl-1-[[(2'-(2-trityl)-2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole 
• 155091-97-7 5-butyl-2-hydroxymethyl-4-iodo-1-<<2'-<(N-triphenylmethyl)tetrazol-5-yl>biphenyl-4-yl>methyl>imidazole 
• 1400933-97-2 5-butyl-4-chloro-2-hydroxymethyl-1-[[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole 
• 1400933-99-4 4-bromo-5-butyl-2-hydroxymethyl-1-[[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole 
• 155091-75-1 5-butyl-2-hydroxymethyl-4-iodo-1-[[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole 
• 155091-94-4 1-<<2'-<(N-triphenylmethyl)tetrazol-5-yl>biphenyl-4-yl>methyl>-5-butylimidazole-2-carboxaldehyde 
• 160540-35-2 5-butyl-1-[[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole-2-carboxaldehyde 

Relevant articles and documents

1,(3,)5-substituted imidazoles, useful in the treatment of hypertension and methods for their preparation

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases.

The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives

A convenient and facile synthesis, in silico docking studies and in vitro biological evaluation of N-substituted 5-butylimidazole derivatives as potent Angiotensin II (ANG II) receptor type 1 (AT1) blockers (ARBs) has been reported in the current study. Our efforts have been directed towards the development of an efficient synthetic route allowing the facile introduction of substituents on the imidazole ring. In particular, a series of imidazole based compounds bearing the biphenyl moiety at the N - 1 position, a halogen atom at the C-4 and polar substituents such as hydroxymethyl, aldo or carboxy group at the C-2 position were designed and synthesized. These compounds were evaluated for binding to human AT1 receptor and for ANG II antagonism in vitro on isolated rat uterus. Among them, 5-butyl-1-[[2′-(2H-tetrazol-5-yl)biphenyl-4-yl] methyl]imidazole-2-carboxylic acid (30) exhibited higher binding affinity compared to the other analogues tested (-log IC50 = 8.46). The latter analogue was also found to be the most active in the rat uterotonic test (pA2 = 7.83). Importantly, the binding affinity was higher to that of losartan (-log IC50 = 8.25) indicating the importance of carboxy group at the C-2 position. Experimental findings are in good agreement with docking studies, which were undertaken in order to investigate ligand/AT1 receptor interactions.

Synthesis of novel biphenyltetrazole derivatives containing 5-methylisoxazole substituted 1,2,4-triazole

An efficient route to synthesize the target compounds was developed. Fifteen new 5-[4′-(5-isoxazol-4-aryl-1,2,4-triazol-3-yl-sulfanylmethyl)- biphenyl-2-yl]-tetrazoles derivatives were synthesized. The structures of the new compounds synthesized were confirmed by elemental analyses and spectral data.